Paclitaxel–bevacizumab combination in advanced non-squamous non-small-cell lung cancer (NSCLC): AVATAX, a retrospective multicentric study

INTRODUCTION: Compared with docetaxel, the phase-III trial, ULTIMATE, showed a significant improvement of progression-free survival (PFS) with paclitaxel–bevacizumab combination (PB) as second- or third-line treatment in advanced non-small cell lung cancer (NSCLC). With the increase of immunotherapy...

Descripción completa

Detalles Bibliográficos
Autores principales: Bilger, Geoffroy, Toffart, Anne-Claire, Darrason, Marie, Duruisseaux, Michaël, Ulmer, Lucie, Wang, Pascal, Leprieur, Etienne Giroux, Girard, Nicolas, Massiani, Marie Ange, Bore, Paul, Descourt, Renaud, Pinsolle, Julian, Valery, Solene, Monnet, Isabelle, Swalduz, Aurélie, Tissot, Claire, Fournel, Pierre, Baranzelli, Anne, Cortot, Alexis B., Decroisette, Chantal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9174558/
https://www.ncbi.nlm.nih.gov/pubmed/35694190
http://dx.doi.org/10.1177/17588359221099399

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9174558/
https://www.ncbi.nlm.nih.gov/pubmed/35694190
http://dx.doi.org/10.1177/17588359221099399

Ejemplares similares